Study Title

A Prospective Study to Evaluate the Lesion Detection Ability of Gallium-68 NODAGA-JR11 for the Diagnostic Imaging of Metastatic, Well-differentiated Neuroendocrine Tumors Using PET/CT

Study Details

Description:

NODAGA-JR11 is a novel somatostatin receptor antagonist, while Gallium-68 DOTATATE is a typical somatostatin receptor agonist. This study is to evaluate the lesion detection ability of Gallium-68 NODAGA-JR11 for the diagnostic imaging of metastatic, well-differentiated neuroendocrine tumors using positron emission tomography / computed tomography (PET/CT). The results will be compared between antagonist Gallium-68 NODAGA-JR11 and agonist Gallium-68 DOTATATE in the same group of patients.

Sponsor:

First Affiliated Hospital of Fujian Medical University

Contacts:

Weibing Miao, MD

miaoweibing@126.com

86-0591-87981618

Shaobo Yao, MD

yaoshaobo008@163.com

86-0591-87981619

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468